Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood.

Autor:	Lee WH; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Graham CE; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Wiggin HR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Nolan HK; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Graham KJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Korell F; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Barselau AL; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Emmanuel-Alejandro E; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Trailor MA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Gildea JM; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., Preffer F; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA., Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Gallagher KME; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2024 May; Vol. 106 (3), pp. 162-170. Date of Electronic Publication: 2024 Feb 28.
DOI:	10.1002/cyto.b.22165
Abstrakt:	Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and idecabtagene vicleucel, for treating relapsed and refractory disease. Although correlative analyses performed by product manufacturers have been reported in clinical trials, there are limited options for reliable BCMA CAR T detection assays for physicians and researchers looking to explore it as a biomarker for clinical outcome. Given the known association of CAR T cell expansion kinetics with toxicity and response, being able to quantify BCMA CAR T cells routinely and accurately in the blood of patients can serve as a valuable asset. Here, we optimized an accurate and sensitive flow cytometry test using a PE-conjugated soluble BCMA protein, with a lower limit of quantitation of 0.19% of CD3+ T cells, suitable for use as a routine assay for monitoring the frequency of BCMA CAR T cells in the blood of patients receiving either ciltacabtagene autoleucel or idecabtagene vicleucel. (© 2024 International Clinical Cytometry Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu